Trial Profile

A Multicenter Phase 1, Open-Label Study of NB003 to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NB 003 (Primary)
Indications Gastrointestinal stromal tumours; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Ningbo NewBay Medical Technology

Most Recent Events

04 Jun 2024 Results (n=42; data cutoff date: 10 Jan 2024) reporting safety and efficacy data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Oct 2023 Results (As of 19 Apr 2023, n=23) assessing safety and tolerability, the MTD, and the RP2D of NB003 in patients (pts) with advanced GIST presented at the 48th European Society for Medical Oncology Congress
23 Aug 2023 Planned number of patients changed from 36 to 258.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com